Pharmaceutical compositions and methods of treating cardiovascular diseases
Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H 1 -receptor agonist, a histamine H 2 -receptor agonist, a histamine H 3 -receptor antagonist, or a β 2 -adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H 1 -receptor agonist, a histamine H 2 -receptor agonist, a histamine H 3 -receptor antagonist, or a β 2 -adrenoreceptor agonist.
1. A method of treating or ameliorating bradycardia in a subject, comprising:
administering to the subject in need thereof a therapeutically effective amount of the pharmaceutical composition comprising:
(i) theophylline or aminophylline 3.2-192 mg/dose;
(ii) nifedipine;
(iii) betahistine; and
(iv) levalbuterol or albuterol.
2. The method of claim 1 , wherein nifedipine 0.16-38.4 mg/dose.
3. The method of claim 1 , wherein betahistine 0.4-120 mg/dose.
4. The method of claim 1 , wherein levalbuterol or albuterol 0.03-9 mg/dose.
5. The method of claim 2 , wherein betahistine 0.4-120 mg/dose.
6. The method of claim 2 , wherein levalbuterol or albuterol 0.03-9 mg/dose.
7. The method of claim 3 , wherein levalbuterol or albuterol 0.03-9 mg/dose.
8. The method of claim 1 , further comprising a pharmaceutically acceptable excipient.
9. The method of claim 1 , wherein the pharmaceutical composition is formulated in a dosage form for oral, intravenous, intramuscular administration.
10. A method of treating or ameliorating bradycardia in a subject, comprising:
administering to the subject in need thereof a therapeutic effective amount of the pharmaceutical composition comprising:
(a) any three compounds, wherein each compound is independently
(i) theophylline or aminophylline 3.2-192 mg/dose;
(ii) nifedipine;
(iii) betahistine or a metabolite thereof; and
(iv) levalbuterol or albuterol.
11. The method of claim 10 , wherein nifedipine 0.16-38.4 mg/dose.
12. The method of claim 10 , wherein betahistine or a metabolite thereof 0.4-120 mg/dose.
13. The method of claim 10 , wherein levalbuterol or albuterol 0.03-9 mg/dose.
14. The method of claim 11 , wherein betahistine or a metabolite thereof 0.4-120 mg/dose.
15. The method of claim 11 , wherein levalbuterol or albuterol 0.03-9 mg/dose.
16. The method of claim 12 , wherein levalbuterol or albuterol 0.03-9 mg/dose.
17. The method of claim 10 , further comprising a pharmaceutically acceptable excipient.
18. The method of claim 10 , wherein the pharmaceutical composition is formulated in a liquid or solid dosage form for oral, intravenous, intramuscular administration.
19. A method of treating or ameliorating bradycardia in a subject, comprising:
administering to the subject in need thereof a therapeutic effective amount of the pharmaceutical composition comprising:
(a) any two compounds, wherein each compound is independently
(i) theophylline or aminophylline 3.2-192 mg/dose;
(ii) nifedipine 0.16-38.4 mg/dose;
(iii) betahistine or a metabolite thereof 0.4-120 mg/dose; and
(iv) levalbuterol or albuterol.
20. The method of claim 19 , further comprising a pharmaceutically acceptable excipient.